Investor Presentation H1 2023

Novo NordiskⓇ 112 Investor presentation First six months of 2023 First efforts to combine Novo Nordisk and partner competencies in cell therapies start with heart failure and Parkinson's disease Heartseed: Phase 1/2 trial in patients with severe heart failure TRANSCEND 1 and 2 trials to evaluate stem cells impact on quality of life for people with moderate Parkinson's disease 10 patients with • Resting LVEF ≤40% • NYHA cardiac HS-001 low dose function classification grade >II HS-001 high dose 26-week follow-up 52-week follow-up Screening Japan 8 participants USA, Sweden, UK 40 participants Open-label transplant surgery or standard of care Double-blinded transplant surgery or sham surgery, or open-label standard of care 2 year primary endpoint 5 year follow-up Objectives to evaluate: • Safety of cardiomyocytes spheroids Efficacy and dose-response Feasibility of transplantation procedures A follow-up phase 2 trial is planned to investigate further dose increase and catheter delivery as route of administration TRANSCEND 1: observational study of patients with moderate PD aiming at identifying potential candidates to the interventional TRANSCEND 2 trial TRANSCEND 2: in combination with Lund University trial, a phase 1/2 trial investigating the treatment of Parkinson's disease Primary endpoint: Number of treatment-emergent adverse events 2 years after dosing PD: Parkinson's disease; LVEF: Left ventricular ejection fraction; NYHA: New York Heart Association

View entire presentation